GCA
TGTX icon

Genesee Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Genesee Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-61,776
Closed -$3.21M – 98
2020
Q4 		$3.21M Buy
+61,776
New +$2.09M 2.1% 15

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Genesee Capital Advisors's TGTX Position: Q1 2021 in Review

Genesee Capital Advisors sold out of TG Therapeutics (TGTX) in Q1 2021, closing a stake of 61,776 shares — an estimated $3.21M sold.

Genesee Capital Advisors first reported a position in TGTX in Q4 2020 and held it in 1 quarter. The position peaked at $3.21M in Q4 2020. 240 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

  • Genesee Capital Advisors reported no remaining TG Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Genesee Capital Advisors sold 61,776 TG Therapeutics shares in Q1 2021, an estimated $3.21M.
  • Genesee Capital Advisors first reported a position in TG Therapeutics in Q4 2020 and held it in 1 quarter.
  • Genesee Capital Advisors's TG Therapeutics position peaked at $3.21M in Q4 2020.
  • 240 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on Genesee Capital Advisors's 13F filing for Q1 2021, filed 16 Apr 2021.